Get the Stockscreener App
22.75
7.96%
1.64
Structure Therapeutics Inc Adr stock is traded at $22.75, with a volume of 458.12K.
It is up +7.96% in the last 24 hours and down -4.44% over the past month.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.
See More
Previous Close:
$21.11
Open:
$21.06
24h Volume:
458.12K
Relative Volume:
0.56
Market Cap:
$1.24B
Revenue:
-
Net Income/Loss:
$-100.44M
P/E Ratio:
-10.25
EPS:
-2.22
Net Cash Flow:
$-105.32M
1W Performance:
+6.40%
1M Performance:
-4.44%
6M Performance:
-41.19%
1Y Performance:
-37.53%
1-Day Range:
$20.94
$23.48
1-Week Range:
$19.89
$23.48
52-Week Range:
$19.39
$62.74
Structure Therapeutics Inc Adr Stock (GPCR) Company Profile
Name
Structure Therapeutics Inc Adr
Sector
Industry
Phone
(628) 229-9277
Address
611 GATEWAY BLVD SUITE 223, SOUTH SAN FRANCISCO
Compare GPCR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GPCR
Structure Therapeutics Inc Adr
|
22.78 | 1.24B | 0 | -100.44M | -105.32M | -2.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
513.86 | 130.83B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.53 | 73.16B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
617.64 | 37.89B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.13 | 32.28B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
265.95 | 28.52B | 3.81B | -644.79M | -669.77M | -6.24 |
Structure Therapeutics Inc Adr Stock (GPCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-28-25 | Initiated | William Blair | Outperform |
| Jan-08-25 | Initiated | Stifel | Buy |
| Dec-04-24 | Initiated | H.C. Wainwright | Buy |
| Sep-23-24 | Initiated | Morgan Stanley | Overweight |
| May-21-24 | Initiated | JP Morgan | Overweight |
| Apr-09-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-19-23 | Initiated | JMP Securities | Mkt Outperform |
| Jul-27-23 | Initiated | Piper Sandler | Overweight |
| May-25-23 | Resumed | Jefferies | Buy |
| Feb-28-23 | Initiated | BMO Capital Markets | Outperform |
| Feb-28-23 | Initiated | Guggenheim | Buy |
| Feb-28-23 | Initiated | Jefferies | Buy |
| Feb-28-23 | Initiated | SVB Securities | Outperform |
View All
Structure Therapeutics Inc Adr Stock (GPCR) Latest News
Acute Bacterial Skin and Skin-Structure Infection Market - openPR
Jones Financial Companies Lllp Raises Stock Position in Structure Therapeutics Inc. (NASDAQ:GPCR) - Defense World
Structure Therapeutics Inc. (NASDAQ:GPCR) Shares Bought by Assetmark Inc. - Defense World
Analysts Update Their Estimates For Structure Therapeutics Inc ADR - Stocks Register
GPCR Stock Hits 52-Week Low at $19.61 Amid Market Challenges - Investing.com Canada
Berberine-inspired ionizable lipid for self-structure stabilization and brain targeting delivery of nucleic acid therapeutics - Nature.com
Archer Aviation Stock Climbs as Midnight eVTOL Nears Reality - The Globe and Mail
Structure Therapeutics (GPCR) Projected to Post Quarterly Earnings on Friday - Defense World
Research Analysts Issue Forecasts for GPCR Q4 Earnings - Defense World
Q1 Earnings Estimate for GPCR Issued By Leerink Partnrs - Defense World
Structure Therapeutics, Inc.: Strong Pipeline and Financial Stability Underpin Buy Rating Despite Price Target Reduction - TipRanks
Structure Therapeutics Inc ADR’s (NASDAQ: GPCR) Stock Price Continues To Fall - Stocks Register
Leerink cuts Structure Therapeutics target to $60, keeps outperform - Investing.com India
Analysts Set Structure Therapeutics Inc. (NASDAQ:GPCR) Target Price at $81.29 - Defense World
Structure Therapeutics (NASDAQ:GPCR) Research Coverage Started at William Blair - Defense World
Heron Therapeutics’ (HRTX) Buy Rating Reiterated at Needham & Company LLC - Defense World
Structure Therapeutics (NASDAQ:GPCR) Coverage Initiated by Analysts at William Blair - MarketBeat
Structure Therapeutics Advances in Obesity Treatment Pipeline - TipRanks
Structure Therapeutics (NASDAQ:GPCR) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPS - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Shares Up 8% on Earnings Beat - MarketBeat
Structure Therapeutics, Inc.: Promising Outlook with Aleniglipron in Obesity Treatment and Strategic Advancements Justify Buy Rating - TipRanks
Promising Potential of Structure Therapeutics’ Aleniglipron: A Compelling Buy Recommendation - TipRanks
JMP cuts Structure Therapeutics price target to $87 - Investing.com
Structure Therapeutics Inc. (NASDAQ:GPCR) Receives $81.29 Average Price Target from Brokerages - MarketBeat
Buy Rating for Structure Therapeutics: Promising Phase 2b Trials and Strong Financial Position - TipRanks
Structure Therapeutics (NASDAQ:GPCR) Hits New 52-Week LowTime to Sell? - MarketBeat
Structure Therapeutics reports Q4 net loss $36.5M vs. net loss $24.5M last year - TipRanks
Structure Therapeutics (NASDAQ:GPCR) Trading Down 6.4%Time to Sell? - MarketBeat
Structure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Highlights - The Manila Times
Can Structure Therapeutics' Obesity Drug Challenge Wegovy? Trial Enrollment Complete - StockTitan
GPCR stock touches 52-week low at $20.11 amid market challenges By Investing.com - Investing.com South Africa
GPCR stock touches 52-week low at $20.11 amid market challenges - Investing.com India
Structure Therapeutics (NASDAQ:GPCR) Trading Up 6.2%Here's Why - MarketBeat
Handelsbanken Fonder AB Purchases Shares of 165,000 Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat
Structure Therapeutics Inc. (NASDAQ:GPCR) Sees Large Decline in Short Interest - MarketBeat
GPCR Stock Hits 52-Week Low at $23.48 Amid Market Challenges - Investing.com Canada
Nebius Group: NVIDIA’s Investment Sparks All-Time Highs - The Globe and Mail
Structure Therapeutics (NASDAQ:GPCR) Sets New 52-Week Low – Here’s What Happened - Defense World
Why Structure Therapeutics Stock Was Stumbling This Week - The Globe and Mail
abrdn plc Sells 45,695 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat
Financial Fitness Check: Examining Structure Therapeutics Inc ADR (GPCR)’s Key Ratios - The Dwinnex
Spire Wealth Management Acquires Shares of 8,949 Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Trading Down 6.7%Should You Sell? - MarketBeat
HSBC Securities Downgrades Morgan Stanley (MS) to a Hold from a Buy - Knox Daily
JD.com Inc ADR (JD) receives an Outperform rating from Bernstein - Knox Daily
Ratio Examination: Bausch Health Companies Inc (BHC)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Brokerages Set Structure Therapeutics Inc. (NASDAQ:GPCR) PT at $81.29 - MarketBeat
Understanding the Recent Fluctuations of Structure Therapeutics Inc ADR’s (GPCR) Stock - The News Heater
Structure Therapeutics Inc. (NASDAQ:GPCR) Short Interest Update - MarketBeat
Structure Therapeutics Inc Adr Stock (GPCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Structure Therapeutics Inc Adr Stock (GPCR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lin Xichen | CHIEF SCIENTIFIC OFFICER |
Jun 03 '24 |
Option Exercise |
0.34 |
106,200 |
36,108 |
191,907 |
0.16%
1.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):